Compare ABUS & SBGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABUS | SBGI |
|---|---|---|
| Founded | 2005 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Broadcasting |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 839.5M | 998.0M |
| IPO Year | 2008 | 2023 |
| Metric | ABUS | SBGI |
|---|---|---|
| Price | $4.73 | $15.09 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | $5.00 | ★ $22.00 |
| AVG Volume (30 Days) | ★ 2.3M | 516.1K |
| Earning Date | 05-14-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 6.56% |
| EPS Growth | ★ 55.26 | N/A |
| EPS | ★ 0.87 | 0.28 |
| Revenue | $14,083,000.00 | ★ $3,169,000,000.00 |
| Revenue This Year | N/A | $12.37 |
| Revenue Next Year | $239.71 | N/A |
| P/E Ratio | ★ $5.52 | $50.89 |
| Revenue Growth | ★ 128.21 | N/A |
| 52 Week Low | $3.08 | $11.89 |
| 52 Week High | $5.10 | $17.88 |
| Indicator | ABUS | SBGI |
|---|---|---|
| Relative Strength Index (RSI) | 64.91 | 61.69 |
| Support Level | $4.15 | $14.54 |
| Resistance Level | $4.85 | $15.49 |
| Average True Range (ATR) | 0.18 | 0.60 |
| MACD | 0.05 | 0.13 |
| Stochastic Oscillator | 85.54 | 92.59 |
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
Sinclair Inc. is the owner-operator of the second largest portfolio of television stations in the United States, with 185 full power stations in 86 markets, covering 40% of US households. Of the firm's roughly 600 channels, 150 are affiliated with the four national broadcasters—Fox, ABC, CBS, and NBC—with over 80 other channels aligned with The CW (Nexstar) and MyNetworkTV (Fox). Sinclair owns the Tennis Channel and stakes in Marquee Sports Network and YES Network, providing their premium sports content to pay-TV distributors.